First, for SMARCA4-WT CDX models, daily single treatment with either GSK-PTi or BBAi-1 had a moderate therapeutic effect, with a tumor growth inhibition (TGI) rate of 23% or 46.9%, respectively, in model mice (Fig. 6b, c, and e). Here, SMARCA4 is linked to neoplasm.